Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABT-122 Open-Label Extension in Rheumatoid Arthritis
NCT02433340Phase 2Completed
- Sponsor
- AbbVie Inc.
- Start
- Apr 2015
- Primary completion
- May 2016
- Modality
- Bispecific Antibodies
01
Overview
A Phase 2 trial of remtolumab in rheumatoid arthritis (RA), sponsored by AbbVie Inc.. Started Apr 2015; status: completed.
02
Drugs
remtolumab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT02433340.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02433340.